Head-to-head evidence
CJC-1134-PC vs HDG1901
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
CJC-1134-PC
Developed by ConjuChem
NCT07058545 · Phase 3 · completed
The study randomized 474 participants to CJC-1134-PC or placebo and blinded participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in HbA1c at Week 25, a surrogate measure, and the registry does not report whether the comparison was favorable or statistically significant.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
HDG1901
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
NCT06739044 · Phase 3 · completed
The trial randomized 494 participants to HDG1901 or active Ozempic treatment, but neither participants nor investigators were blinded. Its primary endpoint was change in HbA1c, a surrogate measure, and the registry does not report whether the comparison met its objective, supporting a moderate evidence grade.
Caveat: source is secondary industry coverage that does not cite the trial registry number; attribution rests on sponsor/program match only.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CJC-1134-PC's landscape · HDG1901's landscape